Cerus (CERS) vs. The Competition Critical Survey
Cerus (NASDAQ: CERS) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it compare to its rivals? We will compare Cerus to similar companies based on the strength of its dividends, analyst recommendations, risk, earnings, institutional ownership, valuation and profitability.
Risk & Volatility
Cerus has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, Cerus’ rivals have a beta of 0.47, suggesting that their average share price is 53% less volatile than the S&P 500.
Insider and Institutional Ownership
58.5% of Cerus shares are owned by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 7.4% of Cerus shares are owned by company insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of recent recommendations for Cerus and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cerus currently has a consensus price target of $6.60, suggesting a potential upside of 82.32%. As a group, “Medical Devices & Implants” companies have a potential upside of 37.14%. Given Cerus’ stronger consensus rating and higher probable upside, research analysts plainly believe Cerus is more favorable than its rivals.
This table compares Cerus and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Cerus and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cerus||$39.28 million||-$62.90 million||-6.14|
|Cerus Competitors||$1.67 billion||$207.58 million||81.12|
Cerus’ rivals have higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Cerus rivals beat Cerus on 7 of the 12 factors compared.
Cerus Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.